Gnomica Biotherapy
Small-molecule Drug Inhibitors Targeting Bacterial Pathways to Treat Cancer
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in June 2025 by Uri Kolodny and Ravid Straussman, Gnomica Biotherapy operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing novel cancer treatments.
Business overview
Gnomica Biotherapy is pioneering a novel approach to cancer treatment by developing small-molecule drug inhibitors. The company's core technology targets bacterial functions within the human body, addressing a critical factor in treatment resistance. Gnomica Biotherapy serves the healthcare and life sciences industries, specifically operating within the pharma and medical biotechnology sectors, with a focus on drug discovery and development for oncology.
Log in to access full profile ›Company Intelligence Q&A
- What is Gnomica Biotherapy's primary focus?
- Gnomica Biotherapy is focused on developing small-molecule drug inhibitors that target bacterial pathways to treat cancer, addressing treatment resistance.
- When was Gnomica Biotherapy founded?
- Gnomica Biotherapy was founded in June 2025.
- Who are the founders of Gnomica Biotherapy?
- Gnomica Biotherapy was founded by Uri Kolodny, who serves as Co-Founder & CEO, and Ravid Straussman, who is Co-Founder & Chief Scientist.
- In which sector does Gnomica Biotherapy primarily operate?
- Gnomica Biotherapy primarily operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.
- What is the current product stage of Gnomica Biotherapy?
- Gnomica Biotherapy's product is currently in the Clinical Trial stage, indicating it is undergoing testing in human subjects to evaluate its safety and efficacy.